Lung Chemoperfusion Improves Relapse-Free Survival after Metastasectomy for Colorectal Cancer
The Thoracic and Cardiovascular Surgeon · 01.12.2025 · 73 (08) · 661-665
DOI: 10.1055/a-2652-7957 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.12.2025. Verfasst von Evgeny Levchenko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, N.N. Petrov National Medical Research Center of Oncology, Pesochny, Saint Petersburg, Russia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Metastasectomy, Lung Neoplasms, Pneumonectomy. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Metastasectomy is a recommended and widely used operation for pulmonary metastases from colorectal cancer (CRC). The main disadvantage of pulmonary metastasectomy is the high rate of metastasis recurrence, which occurs in almost half of patients. To suppress residual pulmonary microfoci, isolated lung chemoperfusion (ILuP) is used, but its effectiveness has not been studied. The results of pulmonary metastasectomy were studied in 160 patients. In 65 patients of the main group, open metastasectomy with isolated chemoperfusion of the lungs was performed; in 95 patients of the control group, standard open or thoracoscopic metastasectomy was performed. The study design included 1:1 pseudorandomization using the nearest neighbor method. For 17 patients who underwent standard metastasectomy and then metastasectomy with ILuP for recurrent pulmonary metastases, these patients themselves were used as the nearest neighbor. For the remaining patients, the matching pairs were selected by the Propensity Score Matching method. After balancing the sample, the main and control groups comprised 41 pairs of observations, which were subjected to further analysis with assessment of relapse-free pulmonary survival according to Kaplan–Meier. Factors influencing survival were studied in the Cox's model. The median recurrence-free survival in patients of the main group who underwent metastasectomy with ILuP was 22.3 months versus 9.1 months in the control group. One-year recurrence-free survival in the main group was 77.5 ± 6.6% versus 38.1 ± 9.1% in the control group. Isolated lung chemoperfusion increases median recurrence-free survival after pulmonary metastasectomy by more than one year for colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic Oncology, N.N. Petrov National Medical Research Center of Oncology, Pesochny, Saint Petersburg, Russia.
- Department of Oncology, I.I. Mechnikov North-Western State Medical University, Saint Petersburg, Russia.
- Department of Thoracic Oncology, State Budgetary Healthcare Institution of Stavropol Region (Stavropol regional Clinical Oncological dispensary), Stavropol, Russia.
- Department of Oncology, I.P. Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.
ORCID-Profile: Evgeny Levchenko, Mikhail Klochkov, Alexander Mikhnin, Nikita Levchenko, Stepan Ergnyan, Oleg Mamontov, Viktoriia Shabinskaya
Zitieren
APA
Levchenko, E., Klochkov, M., Mikhnin, A., Levchenko, N., Ergnyan, S., Mamontov, O., & Shabinskaya, V. (2025). Lung Chemoperfusion Improves Relapse-Free Survival after Metastasectomy for Colorectal Cancer. The Thoracic and Cardiovascular Surgeon, 73(08), 661-665. https://doi.org/10.1055/a-2652-7957
Vancouver
Levchenko E, Klochkov M, Mikhnin A, Levchenko N, Ergnyan S, Mamontov O, et al. Lung Chemoperfusion Improves Relapse-Free Survival after Metastasectomy for Colorectal Cancer. The Thoracic and Cardiovascular Surgeon. 2025;73(08):661-665. doi:10.1055/a-2652-7957
BibTeX
@article{Levchenko2025,
author = {Levchenko, Evgeny and Klochkov, Mikhail and Mikhnin, Alexander and Levchenko, Nikita and Ergnyan, Stepan and Mamontov, Oleg and Shabinskaya, Viktoriia},
title = {Lung Chemoperfusion Improves Relapse-Free Survival after Metastasectomy for Colorectal Cancer},
journal = {The Thoracic and Cardiovascular Surgeon},
year = {2025},
volume = {73},
number = {08},
pages = {661--665},
doi = {10.1055/a-2652-7957}
}
EUVIMED